Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Telix Pharmaceuticals Limited

< Previous 1 2 Next >
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix ADSs Commence Trading on Nasdaq
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Files Form 20-F Registration Statement for Nasdaq ADS
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX CAH
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Reorganisation to Deliver on Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Launch of Proposed Initial Public Offering in the United States
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Submits NDA for New Prostate Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Q1 2024 Revenue and Business Update
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS